MyoKardia Receives $38,000,000 New Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=cc84b3e6-71da-486d-99e6-c6f0f0706ce2&Preview=1 -
Date
9/21/2012 -
Company Name
MyoKardia -
Mailing Address
455 Mission Bay Blvd South San Francisco, CA 94158 -
Company Description
MyoKardia is dedicated to revolutionizing the treatment of cardiovascular disease. The company’s first programs include hypertrophic and dilated cardiomyopathy (HCM and DCM), which together afflict approximately 1 million people in the United States, and for which no novel therapeutics have been brought to market in over a decade. -
Website
http://www.myokardia.com -
Transaction Type
Venture Equity -
Transaction Amount
$38,000,000 -
Transaction Round
Undisclosed -
Proceeds Purposes
The initial plan is to go after hypertrophic cardiomyopathy and dilated cardiomyopathy, with a handful of drugs matched up to specifically treat a handful of different genetic forms of the disease. -
M&A Terms
-
Venture Investor
Third Rock Ventures -
Venture Investor
Undisclosed
